检测CEA和CEA mRNA指标诊断恶性腹水

目的:评估检测癌胚抗原(CEA)和癌胚抗原信使核糖核酸(CEAmRNA)指标在诊断恶性腹水方面的应用价值。方法:研究对象包括恶性腹水组38例、良性腹水组32例,采集腹水为检测标本,应用酶联免疫吸附试验(ELISA)方法检测CEA、反转录套式聚合酶链反应(RT-NP-PCR)技术检测CEAmRNA。结果:CEA的阳性率为恶性腹水组52.6%(20/38)、良性腹水组6.3%(2/32);CEAmRNA的阳性率为恶性腹水组78.9%(30/38)、良性腹水组9.4%(3/32)。检测腹水标本CEAmRNA和CEA指标,诊断恶性腹水的特异性分别为CEA93.8%和CEAmRNA90.6%,敏感性分别为CEA52.6%和CEAmRNA78.9%。结论:在诊断恶性腹水方面,CEA和CEAmRNA指标的特异性均较高,但CEAmRNA指标的敏感性显著性高于CEA指标(P<0.01),更具有应用价值。     

雌、孕激素受体在非小细胞肺癌中的表达及意义

目的　探讨雌激素受体 (ER)、孕激素受体 (PR)在非小细胞肺癌组织中的表达情况。方法　应用S P免疫组化法检测石蜡包埋的肺癌标本中ER、PR。结果　ER、PR的阳性表达率分别为 4 5 .2 %、4 0 .4 % ,其中腺癌的表达明显高于其他组织类型 ;ER、PR的表达与患者的性别、年龄、临床分期、肿瘤细胞分化水平无关 ;1年和 3年术后ER与PR阴阳性患者的非肿瘤生存率差异无统计学意义 (P >0 .0 5 )。结论　肺癌组织中存在ER、PR ,将其作为激素辅助治疗的一个指标 ,有一定的应用前景。     

虎斑游蛇的药理作用研究Ⅱ——急性毒性及镇痛作用

虎斑游蛇提取液小鼠化学刺激及电刺激引起的疼痛均有明显的镇痛作用。灌胃给药的小鼠急性毒性试验LD50未能测现,而小鼠最大耐受量为200g/kg,为成人临床常用剂量的300倍。     

利用CR和PACS对国产X线放疗模拟定位机拍片部分进行数字化改造和传输

介绍了通过对新华SL—IC型X线放疗模拟机部分硬件进行改造和设置放疗科工作站的办法,利用诊断科的CR和医院的PACS．实现了模拟机定位片拍摄的数字化升级。     

胫前区及足部深度烧伤创面修复

目的 寻求胫前区及足部深度烧伤创面修复的合适方法。方法 根据对35例胫前区及足部深度烧伤患者施行不同的组织瓣移位手术经验,讨论各种组织瓣形成的具体方法及注意事项。结果 组织瓣成活优良率达97%,创面修复效果满意。结论 术中根据皮肤软组织缺损类型和范围选择适当的组织瓣,并运用扎实的解剖学基础分离血管神经．是保证手术获得成功的关键。     

Effects of Amiodarone and Its Active Metabolite Desethylamiodarone on the Ventricular Defibrillation Threshold

Objectives. We evaluated whether the reported difference in the ventricular defibrillation threshold (DFT) between short-term intravenous and oral amiodarone is due to the effect of amiodarone’s active metabolite desethylamiodarone (DEA).

Background. Amiodarone is frequently used in patients with implantable cardioverter-defibrillator devices (ICD). Long-term oral amiodarone raises the DFT, but intravenous amiodarone has not been shown to have this effect. DEA, an active metabolite of amiodarone, has different electrophysiologic properties than its parent compound and may be responsible for the observed different effects of intravenous and oral amiodarone on DFT.

Methods. We ascertained the DFT in 24 pigs randomized to receive intravenous amiodarone, DEA or vehicle. Defibrillation was delivered through a transvenous lead system using a biphasic waveform. The DFT was determined using an up-down DFT algorithm and defined as the average minimal energies resulting in successful defibrillation delivered from ascending and descending serial shocks.

Results. Amiodarone caused a dose-response increase in DFT (mean ± SD) from 22.7 ± 4.1 (baseline) to 26.1 ± 2.9 (10 mg/kg body weight), p = 0.11, to 34.9 ± 8.2 J (after an additional 15 mg/kg), p = 0.035. DEA (10 mg/kg) caused an increase in DFT from 20.5 ± 6.3 to 33.9 ± 13.6 J, p < 0.01. Addition of 15 mg/kg of DEA resulted in hemodynamic instability and thus DFT was not obtained. In the control group, DFT decreased from 26.8 ± 7.7 at baseline to 23.1 ± 7.4 (dose 1), p = 0.19, to 22.8 ± 6.2 J (dose 2), p = 0.18.

Conclusions. DEA increases DFT by a greater amount than its parent drug amiodarone. There is an effect of intravenous amiodarone on DFT that is dose dependent.     

Effects of Stellera chamaejasme on microvascular density and apoptosis of cancer cells in a rat bladder tumor model

BackgroundInvestigate the effects of Stellera chamaejasme on microvascular density and apoptosis of cancer cells in rat bladder tumor models.MethodsThe bladder tumor model of 75 specific pathogen-free (SPF)-grade Sprague-Dawley (SD) rats aged 5–6 weeks was established by n-methyl-N-nitrosourea (MNU) bladder perfusion induction, and the model rats were randomly divided into model group, low-dose (L-dose) group, medium-dose (M-dose) group, high-dose (H-dose) group, and positive drug (hydroxycamptothecine, HCPT) group. L-dose group, M-dose group, and H-dose group were treated with 5 g/kg, 10 g/kg, and 20 g/kg, respectively. The HCPT group was treated with 2 mg/kg hydroxycamptothecin at 1 mL/kg once a week and the model group were treated with the same amount of normal saline for 4 weeks. The quality of bladder cancer tissues in each group was measured. The pathological changes and microvascular density of bladder tissues were observed, and the apoptosis rate of vascular endothelial growth factor (VEGF), tumor tissue and the protein expression levels of factor associated suicide (Fas), factor associated suicide ligand (FasL) and Caspase3 in bladder tissues were detected.ResultsBladder cancer was induced 14 weeks after initial bladder perfusion with MNU. In the model group, epithelial cells of bladder tissue showed atypically hyperplasia with various sizes and disorders. After treatment with Stellera chamaejasme, the hematoxylin-eosin (HE) scores, bladder weight, microvascular density, and VEGF were significantly decreased, and the tumor inhibition rate, cell apoptosis, and the expression of apoptosis-related proteins Fas, FasL, and Caspase3 were significantly increased in the bladder tissue. The above changes were dose-dependent with Stellera chamaejasme.ConclusionsMNU can be used to prepare a rat bladder cancer model. Stellera chamaejasme has a good therapeutic effect on rat bladder cancer, which may inhibit the progression of bladder cancer by inhibiting micro-angiogenesis and inducing the apoptosis of bladder tumor cells.     

钒酸钠对患糖尿病大鼠某些器官组织SOD活性的影响

目的 探讨钒酸钠对血浆、肝、肾组织中ＳＯＤ活性的影响,以及ＳＯＤ活性与糖尿病（ＤＭ）动物肝、肾组织学变化的关系。方法 ６０只大鼠随机分为正常对照（ＮＣ）组,自由饮用ＮａＣｌ水,矾酸钠（Ｖ）组,自由饮用ＮａＣｌ＋Ｎａ３ＶＯ４（０．５ｍｇ／ｍｌ）;糖尿病（Ｄ）组;钒酸钠＋糖尿病（ＤＶ）组。测定血、肝、肾组织中的ＳＯＤ活性。并作病理组织学检查。结果 Ｄ组大鼠血浆、肝、肾组织中ＳＯＤ活性降低,ＤＶ组血浆、     

基于“异病同治”理论探讨恒古骨伤愈合剂在4种骨伤科疾病治疗中的应用

“异病同治”是指不同的疾病,在其发展过程中,由于出现了相同的病机,而采用同一方法治疗的法则。恒古骨伤愈合剂由三七、红花、人参、黄芪、杜仲、鳖甲、钻地风、洋金花、陈皮组成,是现代中医临床“异病同治”的一种代表性药物。多项临床研究表明,恒古骨伤愈合剂治疗骨折、股骨头坏死、骨关节炎、腰椎间盘突出症等均取得了较好疗效。虽然现代医学认为这4种骨伤疾病的发病机制不同,但中医学认为其病因病机基本相同,均为瘀血、风湿痹阻、肝肾气血亏虚、经脉筋骨失养所致。恒古骨伤愈合剂针对这4种骨伤疾病“瘀血阻络、筋骨失养”的共同病机遣方用药,具有活血化瘀、散结生新、滋补肝肾、荣筋养骨的功效,充分体现了中医“圆机活法”“异病同治”“辨证用药”的理法特色。同时恒古骨伤愈合剂的现代药理机制研究及临床应用研究,也为其“一药多用”和“异病同治”提供了现代科学依据。本文从中医对4种骨伤疾病发病机理的认识、恒古骨伤愈合剂的方解及其治疗4种骨伤疾病的药理机制和临床运用4个方面,探讨并揭示了恒古骨伤愈合剂能“一药多用”和“异病同治”的科学内涵,为指导临床合理用药提供了借鉴。     

Elevated serum levels of interleukin-10 in adult-onset Still’s disease are associated with disease activity

Clinical Rheumatology - To evaluate the serum levels of the anti-inflammatory cytokine interleukin-10 (IL-10) in patients with adult-onset Still’s disease (AOSD), a rare, systemic, and...